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Abstract 17 
Background: Antimicrobial combination therapy is a time/resource- intensive procedure commonly 18 
employed in the treatment of cystic fibrosis (CF) pulmonary exacerbations caused by P. aeruginosa. 19 
Ten years ago the most promising antimicrobial combinations were proposed, but there has since 20 
been the introduction of new β-lactam+β-lactamase inhibitor antimicrobial combinations. The aims of 21 
this study were i) to compare in vitro activity of these new antimicrobials with other anti-22 
pseudomonals agents and suggest their most synergistic antimicrobial combinations. ii) to determine 23 
antimicrobial resistance rates and study inherent trends of antimicrobials over ten years.  24 
Methods: A total of 721 multidrug-resistant P. aeruginosa isolates from 183 patients were collated 25 
over the study period. Antimicrobial susceptibility and combination testing were carried out using the 26 
Etest method. The results were further assessed using the fractional inhibitory concentration index 27 
(FICI) and the susceptible breakpoint index (SBPI). 28 
Results: Resistance to almost all antimicrobial agents maintained a similar level during the studied 29 
period. Colistin (p<0.001) and tobramycin (p=0.001) were the only antimicrobials with significant 30 
increasing isolate susceptibility while an increasing resistance trend was observed for levofloxacin. 31 
The most active antimicrobials were colistin, ceftolozane/tazobactam, ceftazidime/avibactam, and 32 
gentamicin. All combinations with β-lactam+β-lactamase inhibitors produced some synergistic results. 33 
Ciprofloxacin+ceftolozane/tazobactam (40%) and amikacin+ceftazidime (36.7%) were the most 34 
synergistic combinations while colistin combinations gave the best median SPBI (50.11). 35 
Conclusions: This study suggests that effective fluoroquinolone stewardship should be employed for 36 
CF patients. It also presents in vitro data to support the efficacy of novel combinations for use in the 37 
treatment of chronic P. aeruginosa infections.  38 
Keywords: Pseudomonas aeruginosa; Cystic Fibrosis; Antimicrobial susceptibility testing; Synergy 39 
testing; Etest  40 
1.0 Introduction 41 
In cystic fibrosis (CF) patients, Pseudomonas aeruginosa is the most commonly isolated pathogen and 42 
more than 70% of CF patients are colonized with this bacterium by the age of 25 (1, 2). P. aeruginosa 43 
is the primary cause of acute respiratory exacerbations in CF patients with persistent infections leading 44 
to a progressive decline in pulmonary function (3). It has been established that the presence of P. 45 
aeruginosa in respiratory cultures is a major predictor of mortality and morbidity (2). Therefore, in 46 
clinical practice to improve life expectancy and the quality of life especially for patients awaiting lung 47 
transplantation aggressive antimicrobial treatment is employed (1-3). But the cumulative lifetime 48 
treatment of CF patients with antibiotics leads to the development of multidrug-resistant (MDR) P. 49 
aeruginosa (4). For this reason, various treatment approaches are employed in patient management 50 
to delay the development of multidrug-resistant strains. These approaches include combination 51 
therapy and the use of modified dosing strategies to optimize antimicrobial 52 
pharmacokinetic/pharmacodynamics (PK/PD) parameters. To serve as a guide, ten years ago our lab 53 
published that the most promising in vitro antimicrobial combinations for use in the treatment of 54 
MDR P. aeruginosa infections were based on amikacin and ceftazidime combinations (5). However in 55 
recent times, there has been the development of novel antipseudomonal agents such as 56 
ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (4). As single agents, ceftolozane and 57 
ceftazidime have been reported as the most active antipseudomonal agents. However, coupling these 58 
antimicrobials with tazobactam and avibactam extends the susceptibility pattern of these 59 
antimicrobials to include the extended-spectrum beta-lactamase (ESBL)-producing 60 
Enterobacteriaceae (4).  In vitro investigations reported in BSAC data (UK report) state that 61 
ceftolozane/tazobactam is a potent antipseudomonal antibiotic with higher susceptibility rates than 62 
other β-lactam/β-lactamase inhibitor combinations, carbapenems and fluoroquinolones. 63 
Susceptibility rates have been consistently high over the 9 years analysed (2010–18), with 100%, 64 
99.5%, 99.4%, 99.4-100%, 99%, 100%, 90-100%, 100% and 100% respiratory isolates susceptible to 65 
ceftolozane/tazobactam for each year (6). Similarly, susceptibility rates of ceftazidime/avibactam 66 
were 98.6% for the 2016–17 period and 100% for the 2017–18 period. As a result, these new β-lactam 67 
combinations are effective against many Gram-negative bacilli, including MDR P. 68 
aeruginosa associated with urinary tract infections, nosocomial pneumonia, and complicated 69 
intraabdominal infections as well as in the treatment of acute pulmonary exacerbations in cystic 70 
fibrosis (7-9). However, recent studies including ours (10) have shown that there can be the 71 
development of resistance to these new antimicrobial agents.  72 
The purpose of the current study was to compare the in vitro activity of ceftolozane/tazobactam and 73 
ceftazidime/avibactam with other antimicrobials on CF MDR P. aeruginosa and propose an up-to-date 74 
most promising antimicrobial combination for the treatment of CF MDR P. aeruginosa infections. A 75 
secondary objective was to determine the antimicrobial resistance rates of CF MDR P. aeruginosa and 76 
study inherent trends of these antimicrobials over ten years. This would provide empirical evidence in 77 
the treatment of pulmonary exacerbations. 78 
 79 
2.0 Materials and method  80 
2.1 Study Isolates 81 
Between 13 January 2009 and 02 April 2020, 721 CF-MDR Pseudomonas aeruginosa identified by 10 82 
British laboratories were collected over 10 years when they were sent for extended antimicrobial 83 
susceptibility testing. Isolates were stored in the bacterial preservation system MICROBANKTM (PRO-84 
LAB DIAGNOSTICS Ontario, Canada) at -80oC and were plated on receipt onto Mueller-Hinton agar 85 
(MH), MacConkey agar, Pseudomonas Cetrimide agar and Burkholderia cepacia selective agar plates 86 
(All agar plates were manufactured by Oxoid Ltd., Basingstoke, UK). After 18-24 hr incubation in 87 
ambient air at 35oC, plates were verified for culture purity.  As a confirmatory test, oxidase testing 88 
(Oxoid Ltd., Basingstoke, UK) was performed on 18-24 hr colonies. Isolates were accepted as 89 
Pseudomonas aeruginosa when they were oxidase-positive and non-lactose fermenting. In this study, 90 
multidrug resistance was defined as acquired non-susceptibility to at least one agent in ≥3 91 
antimicrobial groups (11). These isolates were referred to as MDR3 while MDR2 and MDR1 referred 92 
to isolates with resistance to two and one antimicrobial groups respectively.   93 
2.2 Minimum Inhibitory Concentration (MIC) testing 94 
MIC testing was performed on MH Agar using the Etest methodology according to the manufacturer’s 95 
instructions (Liofilchem, Abruzzi, Italy and BioMerieux, Basingstoke, UK). The antimicrobials tested 96 
were the aminoglycosides (amikacin, gentamicin, and tobramycin), fluoroquinolones (ciprofloxacin 97 
and levofloxacin), lipopeptides (colistin), and the β-lactams. Of the β-lactams, mono-agents tested 98 
were monobactams (aztreonam), cephalosporins (ceftazidime), and carbapenems (imipenem and 99 
meropenem) while combinations tested were piperacillin/tazobactam, ticarcillin/clavulanate, 100 
ceftazidime/avibactam, and ceftolozane/tazobactam. Susceptibility of ticarcillin/clavulanate included 101 
in the analyses was up to its stop date (2017) while ceftazidime/avibactam and 102 
ceftolozane/tazobactam were included in the analyses from the time of introduction (Jan 2018). 103 
In this study, MIC values between the standard doubling dilution scale were rounded up to the next 104 
doubling dilution. The MICs for all tested antimicrobials were interpreted as susceptible (S), 105 
intermediate (I) or resistant (R) according to the European Committee on Antimicrobial Susceptibility 106 
Testing (EUCAST) approved interpretive standards for P. aeruginosa (12). Due to changes in EUCAST 107 
breakpoints during the studied period, isolate susceptibility patterns were according to the year of 108 
submission.    109 
2.3 Combination testing 110 
Antimicrobial combination testing for each isolate was performed using a minimum of six pairs of 111 
antimicrobials as previously described (5). Briefly, a saline suspension of 0.5 McFarland standard (1.0 112 
for mucoid strains) from 24hr cultures was inoculated onto MH agar plates according to the EUCAST 113 
guidelines for the disk diffusion plate inoculation. Two Etest strips (A and B) were placed top-to-tail 114 
according to the manufacturer’s instructions. After 1hr to allow antimicrobial diffusion into the agar, 115 
each strip was removed and replaced with a fresh Etest (i.e. Etest A strip replaced with fresh Etest B 116 
strip and vice versa). Plates were further incubated for 18±2hr in ambient air at 35±1oC.  117 
2.3.1 Fractional inhibitory concentration index (FICI) 118 
Synergy MIC was expressed using the FICI and calculated as described below. 119 
FICI = (MIC A combination / MIC A single) + (MIC B combination / MIC B single). 120 
If an MIC value was greater than the antimicrobial range tested, the next doubling dilution above this 121 
value of the range tested was used to calculate the FICI (e.g. if an MIC of >32mg/L was found then the 122 
FICI was calculated using 64mg/L) (13). These indices were interpreted as synergy - FICI ≤0.5, no 123 
interaction - FICI >0.5 and ≤4.0, and antagonism - FICI >4.0 (14). 124 
Analyses of species susceptibility to synergy combinations (≥10 replicates) of tested antimicrobials 125 
were carried out when EUCAST breakpoints for P. aeruginosa was known.  126 
2.3.2 Susceptible breakpoint index (SBPI) 127 
The SBPI was used to describe synergy analysis and calculated as described below. 128 
SBPI = (Susceptible breakpoint of antimicrobial A / MIC of antimicrobial A combination) + (Susceptible 129 
breakpoint of antimicrobial B / MIC of antimicrobial B combination) (5). These combination results were 130 
categorised in rank order of their decreasing SBPI results. All antagonistic (FICI >4.0) combinations 131 
irrespective of the SBPI result were not ranked nor recommended for therapy. 132 
 133 
2.4 Statistical methods 134 
Statistical analysis of categorical and continuous variables were carried out using Microsoft Office 135 
Excel 2013 and IBM SPSS statistics for windows, Version 24 (IBM Corp., Armonk, N.Y., USA). The One-136 
way ANOVA with Duncan post hoc test was used for continuous data while the Kruskal Wallis test was 137 
used for comparing categorical data. 138 
 139 
3.0 Results 140 
3.1 Study Isolates 141 
During the study period, 721 MDR P. aeruginosa isolates from 104 female and 79 male CF patients 142 
were referred for extended susceptibility testing from 8 Scottish hospitals while others were from York 143 
and Belfast. The median age at first referral was 27 years (range 7-69 years) and with a median of 3 144 
samples, between 1 and 20 isolates were submitted per patient during the study period.  145 
Figure 1 shows that 69% (496/721 isolates) of the submitted isolates were resistant to the three 146 
groups of antimicrobials (MDR3) tested while 22% (158/721) of submitted isolates were resistant to 147 
only two groups (MDR2). Of the latter, 81% (129/158) of MDR2 isolates showed resistance to the 148 
fluoroquinolones and β-lactams.   149 
3.2 Antimicrobial Susceptibility profile 150 
The results of MIC tests (Figure 2) carried out on 721 isolates showed that the most active 151 
antimicrobial agents were colistin (R=7%), followed by the new β-lactam combinations; 152 
ceftolozane/tazobactam (R=37%) and ceftazidime/avibactam (R=47%). Interestingly, P. 153 
aeruginosa isolates were resistant to the β-lactam combinations; piperacillin/tazobactam (67%) and 154 
ticarcillin/clavulanate (86%). Most of the P. aeruginosa isolates were resistant to the 155 
fluoroquinolones-ciprofloxacin (89%) and levofloxacin (93%) while <70% resistance was observed for 156 
the aminoglycosides with lower resistance rates in gentamicin (36%). In summary, 20% of isolates 157 
were susceptible while 63.9% were resistant to all tested antimicrobials. The fluoroquinolones had 158 
the most resistant isolates (90.83%) followed by β-lactam (67.88%) and aminoglycosides (56.68%). 159 
3.3 Antimicrobial Resistance trend 160 
When the annual mean MIC values for each antimicrobial agent were analysed (Table 1), colistin was 161 
the only antimicrobial which showed a downward trend (R2=0.48) while upward trends were observed 162 
for the fluoroquinolones especially for levofloxacin (R2=0.44). Similarly, an upward trend was observed 163 
in the β-lactams group of which meropenem (R2=0.4967) and piperacillin/tazobactam (R2=0.3007) 164 
demonstrated the greatest increase. The trends for the aminoglycosides during the study period were 165 
level (R2≤0.005).  166 
We analysed our data to determine if there were any statistically significant differences in the annual 167 
means for each antimicrobial. Analysis using the one-way ANOVA showed there was a statistically 168 
significant difference in the annual mean MICs of all tested antimicrobials except tobramycin (p=0.52), 169 
ceftazidime (p=0.19), and ceftazidime/avibactam (p=0.19).  170 
Therefore, we investigated whether observed increases in annual antimicrobial MICs corresponded to 171 
temporal increases in annual resistant strains by assessing time-based differences in resistance to each 172 
tested antimicrobial. Table 2 shows that amongst the aminoglycosides, there were statistically 173 
significant differences (p=0.001-0.041) in the decrease of resistant isolates with tobramycin exhibiting 174 
the sharpest decrease (R2=0.5633). In contrast, levofloxacin (R2=0.472) showed an upward trend but 175 
this was not statistically significant. For the β-lactams group (except imipenem), a statistically 176 
significant resistance increase to meropenem (p=0.01), piperacillin/tazobactam (p<0.001), and 177 
ticarcillin/clavulanate (p=0.024) were observed while statistically significant resistance decrease to 178 
ceftazidime (p=0.017) and aztreonam (p=0.024) in resistance rates (R2≤ 0.1) were observed. 179 
Interestingly, longitudinal analyses of isolates for colistin resistance showed that there was a 180 
statistically significant continuous decrease (R2=0.6881, p<0.001) in resistant isolates during the study 181 
period.  182 
3.4 Antimicrobial Synergy testing 183 
A total of 4062 antimicrobial combinations tests were performed using different antimicrobial pairs. 184 
Overall, 0.01% antagonism and 9.97% synergy were observed for all the tested combinations. In the 185 
antimicrobial groups, 10.31% synergy was observed for aminoglycosides (n=1290), 9.30% for 186 
fluoroquinolones (n=774), and 10.20% for β-lactams (n=2196) while low synergy rates (3.84%) were 187 
observed for colistin (n=964). Of these, the β-lactam (cephalosporin) with aminoglycoside (n=281) as 188 
well as β-lactam+β-lactamase inhibitor antimicrobials (n=19) with another β-lactam (carbapenems) 189 
gave the highest synergy values 20.64 and 26.32% respectively. Table 3 shows that the highest synergy 190 
was observed with antimicrobial combinations of ciprofloxacin and ceftolozane/tazobactam (n=15, 191 
40% synergy) followed by amikacin and ceftazidime (n=60, 36.7% synergy). Similarly, combinations 192 
with ceftazidime were synergistic in 6/7 tested combinations. No synergy was observed when 193 
antimicrobial combinations of colistin with levofloxacin/ceftazidime or imipenem with 194 
tobramycin/ciprofloxacin were tested. In addition, table 3 shows that synergy was observed in all the 195 
tested combinations with the β-lactam+β-lactamase inhibitor antimicrobials (n=12) with 196 
ceftolozane/tazobactam combinations the most synergistic. Indeed, this antimicrobial combination 197 
gave the highest synergy rate (n=82, 23.17% synergy). Synergy rates for ceftazidime/avibactam were 198 
not analysed as only one combination was synergistic.   199 
  200 
4.0 Discussion 201 
The use of antimicrobials has been demonstrated to greatly improve the life expectancy of CF patients 202 
(15). However, a major drawback of this management approach is the development of antimicrobial 203 
resistance due to exposure to several multiple antimicrobial cocktails (1-4, 16). To manage infective 204 
pulmonary exacerbations, CF patients are treated with antimicrobial combinations of which one/both 205 
are generally effective as single agents and there is a lack of evidence guiding the clinician to decide 206 
the best antimicrobial combination that would give a positive treatment outcome (5). Our study 207 
focused on P. aeruginosa, Bullington et al. (17) reported that 62% of healthcare providers and 56% of 208 
people living with CF are concerned about antimicrobial-resistant infections from P. 209 
aeruginosa and Burkholderia spp. This study analysed the multi and extensively drug-resistant isolates 210 
received by our CF antimicrobial reference laboratory, and hence does not provide a representative 211 
picture of the general CF population. Nonetheless, as previously reported by studies sampling CF 212 
patients (5) we observed colistin (93% susceptible) was the most active antimicrobial. These results 213 
should be interpreted with care because for colistin susceptibility testing, it is advised that the use of 214 
micro broth dilution should be employed (12) but our lab used the Etest method. In keeping with the 215 
same study (5) ciprofloxacin was the most active fluoroquinolone. However, we show that a steady 216 
upward trend in annual MIC values was observed for the quinolone antimicrobial class. This 217 
predominance of fluoroquinolone-resistant isolates in our study population may be linked to the use 218 
of ciprofloxacin for first isolates or patients chronically infected with P. aeruginosa as per European 219 
guidelines (18). Fluoroquinolones are used in the treatment of a range of infections due to its safety, 220 
oral bioavailability, and broad-spectrum activity (19, 20). Despite several guidelines to limit the use of 221 
fluoroquinolones in human and veterinary medicine, quinolone-resistance in all species targeted by 222 
this antimicrobial class has been growing steadily (19-23). Also, our data suggest that for the 223 
aminoglycosides (especially tobramycin) and colistin there was an increase in P. aeruginosa 224 
susceptibility rates but in contrast, for the fluoroquinolones, we observed that there was a ~50% 225 
upward trend in the resistance to levofloxacin. Therefore, we agree with Cogen et al., (15) who 226 
reported that although antimicrobial stewardship in this patient population is challenging, its role and 227 
impact would enrich patient management and care.  228 
In this study, ceftolozane/tazobactam and ceftazidime/avibactam were observed as the most 229 
susceptible β-lactam antimicrobials tested. However, our susceptibility rates was lower in contrast 230 
with previous studies which reported in vitro activity of ceftolozane/tazobactam (85.1%) against P. 231 
aeruginosa as comparable with the activity of colistin (89.4%) (24). Gramegna et al. (25) working on 232 
120 CF-derived P. aeruginosa isolates demonstrated that the lowest percentage of in vitro drug 233 
resistance was observed using ceftolozane/tazobactam with 84.2% susceptibility rates. A plausible 234 
explanation of the difference in susceptibility rates might be the study isolate population; their study 235 
was composed of 55% susceptible strains therefore increasing the susceptibility rates. Indeed, 236 
Zamudio et al. (10) reported lower susceptibility values (50%) and Finklea et al. (26) agreed that lower 237 
susceptibility values (30%) were observed if the isolate population differed. Similarly, Mirza et al. 238 
proposed that previous studies had reported a susceptibility rate of 65.4 - 94% for 239 
ceftolozane/tazobactam and 51.8 to 92% for ceftazidime/avibactam in meropenem-non-susceptible 240 
isolates (27). Several resistance mechanisms have been proposed, for example, our laboratory 241 
characterising resistance mechanisms in P. aeruginosa showed it is due to mutation in the AmpC β-242 
lactamase, loss of outer membrane porin D (OprD) while ceftolozane/tazobactam and 243 
ceftazidime/avibactam double resistance is associated with AmpD β-lactamase variations (10). 244 
However, more research is important to determine other resistance mechanisms that would help 245 
develop effective strategies to cope with drug resistance and for epidemiological studies. 246 
To improve efficacy while preventing the emergence of drug resistance, antimicrobial combinations 247 
are often prescribed in the management of CF patients (5). However, the selection of an optimal 248 
combination remains a continual clinical challenge. In a previous work published by our laboratory (5), 249 
antimicrobial combination of amikacin+ceftazidime was stated as the most synergistic combination. 250 
This present study reiterates the dominance of this combination as one of the most synergistic 251 
combination. Interestingly, Nazli et al. (28) demonstrated a 15% synergy using amikacin+ceftazidime 252 
antimicrobial combinations. Furthermore, our analysis demonstrate that combinations with β-lactam 253 
combinations were synergistic. Indeed, newer β-lactam combinations with ciprofloxacin, tobramycin, 254 
and meropenem showed promising results (>25% synergy). The most promising antimicrobial 255 
combination in the present study was ciprofloxacin+ceftolozane/tazobactam. On the basis of our data 256 
suggesting in vitro effectiveness of ciprofloxacin antimicrobial combinations with 257 
ceftolozane/tazobactam, we propose that this combination is explored in clinical care particularly on 258 
the backdrop of restrictions in fluoroquinolone usage. The use of this combination therapy may reduce 259 
the likelihood of the emergence antimicrobial resistance and achieve multi-target engagements 260 
through inhibition of DNA replication and cell wall biosynthesis.  The use of SBPI was proposed earlier 261 
(5) as index for ranking in vitro effectiveness of combinations. Our results suggest that combinations 262 
of colistin with several antimicrobials can give high SBPI values while not predicting synergism as 263 
measured by FICI. Though the reason for this is unclear, we hypothesize that while both indices use 264 
the combination MIC, SBPI compares it with the organisms’ susceptible breakpoint while FICI employs 265 
the single agent MIC. 266 
We acknowledge several limitations to this study, the study population consisting of mainly multidrug-267 
resistant isolate population might have impacted our observations. Also, the choice of antimicrobials 268 
and its combination cut-off (≥10 times) might have impacted on our results. For example, it would 269 
have made our data richer if other newer combinations such as cefiderocol which has low affinity for 270 
AmpC β-lactamases and active against carbapenem-non-susceptible isolates were used in 271 
susceptibility/synergy testing.  272 
In summary, this research reiterates the upward trend in fluoroquinolones resistance and the increase 273 
in susceptibility to colistin and aminoglycosides in CF isolates suggesting effective antimicrobial 274 
stewardship for these antimicrobial agents.  It also gives empirical in vitro evidence that antimicrobial 275 
combinations with β-lactam+β-lactamase inhibitors may be the best synergistic antimicrobial 276 
combinations to use in the treatment of chronic P. aeruginosa infections. 277 
  278 
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 388 
7.0 Figure Legends 389 
Figure 1. Resistance profile of study isolates to antimicrobial groups. Antimicrobial agents in the 390 
aminoglycoside group are Amikacin, Gentamicin and Tobramycin. Levofloxacin and Ciprofloxacin are 391 
grouped as fluoroquinolones while Aztreonam, Ceftazidime, Meropenem, Imipenem are grouped as 392 
the β-lactams. Also included in this group are β-lactams combinations; Piperacillin/Tazobactam, 393 
Ceftazidime/Avibactam, Ticarcillin/Clavulanate and Ceftolozane/tazobactam.  394 
 395 
 396 
Figure 2. Pseudomonas aeruginosa MIC susceptibility patterns to tested antimicrobials. Percentage 397 
of susceptible isolates are represented by green bars while orange and blue bars represent 398 
Intermediate and resistant isolates. 399 
 400 
* Pip/Tazo, Piperacillin/Tazobactam; Tic/Clav, Ticarcillin/Clavulanate; Ceft/Tazo, 401 
Ceftolozane/tazobactam; Cef/Avi, Ceftazidime/Avibactam. 402 
 403 
Table 1. Temporal variations in MIC values for CF derived P. aeruginosa (n=721)  404 
* Pip/Tazo, Piperacillin/Tazobactam; Tic/Clav, Ticarcillin/Clavulanate; Ceft/Tazo, 405 
Ceftolozane/tazobactam; Cef/Avi, Ceftazidime/Avibactam. 406 
 407 
 ND: Not determined 408 
 NS: Non significant 409 
 410 
 411 
Table 2. Temporal differences of antimicrobial resistance of CF derived MDR Pseudomonas 412 
aeruginosa  413 
a 
AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LVX, levofloxacin; ATM, 414 
aztreonam; CAZ, ceftazidime; TZP, piperacillin/tazobactam; IPM, imipenem; MEM, meropenem; COL, 415 
colistin; TIM, ticarcillin/clavulanate; CZA, ceftazidime/avibactam; C/T, ceftolozane/tazobactam 416 
b 
Percentage of resistant isolates 417 
ND: Not determined 418 




Table 3. Summary of results for combinations tested ≥10 times for CF-derived MDR Pseudomonas 423 
aeruginosa 424 
a 
AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LVX, levofloxacin; ATM, 425 
aztreonam; CAZ, ceftazidime; TZP, piperacillin/tazobactam; IPM, imipenem; MEM, meropenem; COL, 426 
colistin; TIM, ticarcillin/clavulanate; CZA, ceftazidime/avibactam; C/T, ceftolozane/tazobactam 427 
b 
Percentage susceptible when used as a single agent 428 
c  
Number of times the combinations were tested 429 
 430 
